# Paclitaxel and Estramustine in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

> **NCT00021372** · PHASE2 · COMPLETED · sponsor: **Fox Chase Cancer Center** · enrollment: 25 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** estramustine phosphate sodium
- **DRUG:** paclitaxel

## Key facts

- **NCT ID:** NCT00021372
- **Lead sponsor:** Fox Chase Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1996-02
- **Primary completion:** 2006-09
- **Final completion:** 2006-09
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2013-07-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00021372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00021372, "Paclitaxel and Estramustine in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00021372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*